RECEIVED

MAY 1 6 2003

TECH CENTER 1600/2900



CDR2	50 AISGSGGSTYYADSVKG AISGSGGSTYYADSVKG			VTVSR	VTVSR
	LEWVS			WGQGTLVTVSR	WGQGTLVTVSR
	40 WVRQAPGKGLEWVS WVRQAPGKGLEWVS	CDR3			GVGAFRPYRKHE
CDR1	SYAMS	O	~	SLPK	
			98	RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR	RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR
	10 20 QVQLVESGGGLVQPGGSLRLSCA <u>V</u> SGFTFS EVQLVESGGGLVQPGGSLRLSCA <u>A</u> SGFTFS		06	ZMNSLRAEI	ZMNSLRAEI
	10 GGLVQPG(GGLVQPG(80	SKNTLYL(SKNTLYL(
	QVQLVESG		70	RFTISRDN	RFTISRDN
	CGS1 CGS2			CGS1	CGS2



RECEIVED

MAY 1 6 2003

TECH CENTER 1600/2900

CDRZ	50 Y GKNNRPS	Y GKNNRPS			FGGGIKLTVLG	IKLTVLG
	APVLVI	APVLVI		100		FGGG
	40 WYQQKPGQAPVLVIY	QGDSLRSYYAS WYQQKPGQAPVLVIY	CDR3	06	NSSPVVLNGVV	NSSPFFHNLVV FGGGIKLTVLG
CDRI	30 QGDSLRSYYAS	RSYYAS				
	OGDSL	OGDSL		80	AEDEAD	AEDEAD
	20 TVRITC	TVRITC			LTTTGAQ	LTTTGAQ
	o 'SVALGQ'	'SVALGQ'		70	SGNTAS	SGNTAS
	10 SSELTQDPAVSVALGQTVRITC	SSELTQDPAVSVALGQTVRITC		09	GIPDRFSGSSSGNTASLTTTGAQAEDEADYYC	GIPDRFSGSSSGNTASLTTTGAQAEDEADYYC
	CGS1	CGS2			CGS1	CGS2

FIG. 1B







FIG. 2A






IST-6	+	1	+	i	1	1
BC-1	ı	+	I	+	i	ı
CGS-2	I	+	ı	+	+	+
CGS-1	ı	+	I	+	1	1
	rec FN 2-11 (B-)	rec FN 2-11 (B+)	rec FN 7-9 (B-)	rec FN 7-9 (B+)	fusion protein λ ED-B	fusion proteinλchFN 60
2	2 3 4 5 6 7 8 9 10 11	2 3 4 5 6 7 8 8 9 10 11		7 8 8 9		fus

FIG. 3A










FIG. 4

```
48 h
     24 h
         scFv(28SI)
scFv(CGS-2) [large necrotic tumour]
  scFv(CGS-2) [small tumour]
        b
```





72 h 48 h 24 h scFv(CGS-1) b scFv(CGS-1)₂ b $scFv(D1.3)_2$ b b = bladdert = tumour